BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38126617)

  • 1. Clinical and morphological features of large-cell neuroendocrine carcinomas and small-cell lung carcinomas expressing the DLL3 and ASCL1 oncoproteins.
    Prieto TG; Baldavira CM; Machado-Rugolo J; Olivieri EHR; Silva ECAD; Silva VG; Ab'Saber AM; Takagaki TY; Capelozzi VL
    Braz J Med Biol Res; 2023; 56():e12921. PubMed ID: 38126617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.
    George J; Walter V; Peifer M; Alexandrov LB; Seidel D; Leenders F; Maas L; Müller C; Dahmen I; Delhomme TM; Ardin M; Leblay N; Byrnes G; Sun R; De Reynies A; McLeer-Florin A; Bosco G; Malchers F; Menon R; Altmüller J; Becker C; Nürnberg P; Achter V; Lang U; Schneider PM; Bogus M; Soloway MG; Wilkerson MD; Cun Y; McKay JD; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Lemaitre N; Soltermann A; Weder W; Tischler V; Brustugun OT; Lund-Iversen M; Helland Å; Solberg S; Ansén S; Wright G; Solomon B; Roz L; Pastorino U; Petersen I; Clement JH; Sänger J; Wolf J; Vingron M; Zander T; Perner S; Travis WD; Haas SA; Olivier M; Foll M; Büttner R; Hayes DN; Brambilla E; Fernandez-Cuesta L; Thomas RK
    Nat Commun; 2018 Mar; 9(1):1048. PubMed ID: 29535388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
    Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
    Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection.
    Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
    Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
    Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
    Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
    Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
    Metro G; Ricciuti B; Chiari R; Baretti M; Falcinelli L; Giannarelli D; Sidoni A; Mountzios G; Crinò L; Bellezza G; Rebonato A; Ferolla P; Toschi L
    Lung Cancer; 2016 May; 95():82-7. PubMed ID: 27040856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
    Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
    Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic findings of bronchial brush cytology for pulmonary large cell neuroendocrine carcinomas: comparison with poorly differentiated adenocarcinomas, squamous cell carcinomas, and small cell carcinomas.
    Kakinuma H; Mikami T; Iwabuchi K; Yokoyama M; Hattori M; Ohno E; Kuramoto H; Jiang SX; Okayasu I
    Cancer; 2003 Aug; 99(4):247-54. PubMed ID: 12925987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.
    Simbolo M; Barbi S; Fassan M; Mafficini A; Ali G; Vicentini C; Sperandio N; Corbo V; Rusev B; Mastracci L; Grillo F; Pilotto S; Pelosi G; Pelliccioni S; Lawlor RT; Tortora G; Fontanini G; Volante M; Scarpa A; Bria E
    J Thorac Oncol; 2019 Sep; 14(9):1651-1661. PubMed ID: 31085341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors.
    Metovic J; La Salvia A; Rapa I; Napoli F; Birocco N; Pia Bizzi M; Garcia-Carbonero R; Ciuffreda L; Scagliotti G; Papotti M; Volante M
    Endocr Pathol; 2022 Sep; 33(3):388-399. PubMed ID: 35608806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases.
    La Rosa S; Marando A; Gatti G; Rapa I; Volante M; Papotti M; Sessa F; Capella C
    Hum Pathol; 2013 Jul; 44(7):1391-9. PubMed ID: 23375646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
    Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
    Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung.
    Beasley MB; Lantuejoul S; Abbondanzo S; Chu WS; Hasleton PS; Travis WD; Brambilla E
    Hum Pathol; 2003 Feb; 34(2):136-42. PubMed ID: 12612881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
    Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
    Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomere length, telomerase activity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pulmonary neuroendocrine tumors.
    Nishio Y; Nakanishi K; Ozeki Y; Jiang SX; Kameya T; Hebisawa A; Mukai M; Travis WD; Franks TJ; Kawai T
    Jpn J Clin Oncol; 2007 Jan; 37(1):16-22. PubMed ID: 17060405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
    Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
    Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
    Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
    Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.